KUALA LUMPUR, Nov 24 -- Humanigen Inc (Humanigen), a clinical stage biopharmaceutical company has established Humanigen Australia Proprietary Limited (Humanigen Australia Pty Ltd) to facilitate Asia-Pacific growth plans.
Through the establishment, Humanigen intends to assess potential partnering opportunities, facilitate clinical development programmes, and conduct other corporate and business development activities in the region.
According to a statement, the first of these was announced on Nov 3, with the execution of a licensing agreement for lenzilumab for South Korea and the Philippines.
“Humanigen’s expansion strategy in COVID-19 includes conducting regional clinical trials, local manufacturing, partnering and potential early market entry,” said Humanigen Head of Asia-Pacific Region, Bob Atwill.
“Some of these opportunities may allow Humanigen Australia Pty Ltd to benefit from certain financial and tax incentives offered by the Australian government, including a potential 43.5 per cent rebate on eligible research and development expenditures.”
The clinical trials that are ongoing, or in advanced planning in Australia comprise lenzilumab in cancer patients who are COVID-19 positive and have pneumonia as part of the C-SMART (COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomized Trial).
The C-SMART study is led by the National Centre for Infections in Cancer at Peter MacCallum Cancer Centre and will be conducted at five Australian sites in Melbourne and Sydney.
In addition, Humanigen is in advanced planning for a Phase 2 study of lenzilumab in combination with azacitidine in newly-diagnosed chronic myelomonocytic leukemia (CMML) patients who express NRAS/KRAS/CBL mutations.
More details at www.humanigen.com.
-- BERNAMA
No comments:
Post a Comment